Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
Conditions
Invasive Mould Infection
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
U. of Alabama at Birmingham, Birmingham, Alabama, United States
UC Davis Medical Center, Sacramento, California, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
U. of Michigan, Ann Arbor, Michigan, United States
Washington U., St Louis, Missouri, United States
U. of Texas, MD Anderson, Houston, Texas, United States
AZ Sint-Jan Brugge, Bruges, Belgium
Universite Libre de Bruxelles (ULB) - Institut Jules Bordet, Brussels, Belgium
UZ Leuven, Leuven, Belgium
Juravinski Hospital, Hamilton, Ontario, Canada
Centre Hospitalier d'Argenteuil, Argenteuil, France
AP-HP Hopital Henri Modor, Créteil, France
Istituto Europeo di Oncologia, Milan, Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS- Universita Cattolica del Sacro Cuore, Roma, Italy
Hospital del Mar, Barcelona, Spain
Hospital Universitario Vall d'Hebron, Barcelona, Spain
Hospital Clinic Barcelona, Barcelona, Spain
Hospital Clinico Universitario de Salamanca, Salamanca, Spain
Study leads
Taylor G. Sandison, MD
Study Director
Sponsor: Elion Therapeutics, Chief Medical Officer